Iovance Biotherapeutics, Inc.
US ˙ NasdaqGM ˙ US4622601007

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Weiser. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael Weiser has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IOVA / Iovance Biotherapeutics, Inc. Director 112,632
US:ZIOP / Alaunos Therapeutics Inc Director 224,282
Director 40,000
US:CHTP / Chelsea Therapeutics International, Ltd. Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Weiser. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IOVA / Iovance Biotherapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IOVA / Iovance Biotherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-31 IOVA WEISER MICHAEL 2,187 6.7900 2,187 6.7900 14,850 77 13.0500 13,691 92.20
2022-05-31 IOVA WEISER MICHAEL 7,813 6.8000 7,813 6.8000 53,128

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Sales IOVA / Iovance Biotherapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IOVA / Iovance Biotherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Purchases TCRT / Alaunos Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IOVA / Iovance Biotherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TCRT / Alaunos Therapeutics, Inc. Insider Trades
Insider Sales TCRT / Alaunos Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IOVA / Iovance Biotherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2011-05-25 ZIOP WEISER MICHAEL 15,000 6.5300 15,000 6.5300 97,950 131 3.85 -40,200 -41.04

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TCRT / Alaunos Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael Weiser as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-06-02 2022-05-31 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
P - Purchase 7,813 112,632 7.45 6.80 53,128 765,898
2022-06-02 2022-05-31 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
P - Purchase 2,187 104,819 2.13 6.79 14,850 711,721
2021-07-01 2021-06-29 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2020-06-10 2020-06-08 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2019-06-11 2019-06-10 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 50,000 50,000
2018-07-19 2018-07-17 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2018-03-19 2018-03-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 50,000 50,000
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
183,748
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
134,600
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
183,748
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
134,600
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
183,748
2018-03-19 3 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
134,600
2018-01-03 2017-12-30 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -6,021 224,282 -2.61 4.14 -24,927 928,527
2018-01-03 2017-12-29 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
A - Award 17,258 230,303 8.10
2017-12-11 2017-12-08 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (right to buy)
M - Exercise -20,000 0 -100.00
2017-12-11 2017-12-08 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -12,325 213,045 -5.47 4.43 -54,600 943,789
2017-12-11 2017-12-08 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
M - Exercise 20,000 225,370 9.74 2.73 54,600 615,260
2017-06-14 2017-06-12 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (Right to Buy)
M - Exercise -15,000 0 -100.00
2017-06-14 2017-06-12 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -13,300 205,370 -6.08 5.47 -72,751 1,123,374
2017-06-14 2017-06-12 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
M - Exercise 15,000 218,670 7.36 4.85 72,750 1,060,550
2017-05-24 2017-05-18 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 40,000
2017-01-04 2016-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -9,331 203,670 -4.38 5.35 -49,921 1,089,634
2017-01-04 2016-12-30 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
A - Award 17,204 213,001 8.79
2016-05-26 2016-05-25 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 40,000
2016-04-20 2016-04-19 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (right to buy)
M - Exercise -15,000 0 -100.00
2016-04-20 2016-04-19 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -10,751 195,797 -5.21 8.88 -95,469 1,738,677
2016-04-20 2016-04-19 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
M - Exercise 15,000 206,548 7.83 5.01 75,150 1,034,805
2016-01-05 2015-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
A - Award 26,661 191,548 16.17
2016-01-05 2015-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -2,047 164,887 -1.23 8.31 -17,011 1,370,211
2015-05-26 2015-05-20 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 40,000
2015-03-05 2015-03-03 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 75,000 75,000
2015-01-02 2014-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (right to buy)
A - Award 25,000 25,000
2015-01-02 2014-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -2,047 166,934 -1.21 5.07 -10,378 846,355
2015-01-02 2014-12-30 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -2,051 168,981 -1.20 5.03 -10,317 849,974
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -50,000 0 -100.00 4.67 -233,500
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -8,802 0 -100.00 3.82 -33,624
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -30,000 0 -100.00 3.18 -95,400
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -27,500 0 -100.00 0.76 -20,900
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -30,000 0 -100.00 4.66 -139,800
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -30,000 0 -100.00 3.48 -104,400
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -30,000 0 -100.00
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -30,000 0 -100.00 1.90 -57,000
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -35,000 0 -100.00 5.29 -185,150
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -17,500 0 -100.00 5.34 -93,450
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -52,500 0 -100.00 5.48 -287,700
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
D - Sale to Issuer -52,500 0 -100.00 1.79 -93,975
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
M - Exercise -27,500 0 -100.00
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Common Stock
D - Sale to Issuer -27,500 0 -100.00
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Common Stock
M - Exercise 27,500 27,500 6.50 178,750 178,750
2014-06-25 2014-06-23 4 CHTP Chelsea Therapeutics International, Ltd.
Common Stock
U - Other -450,178 0 -100.00
2014-06-02 2014-05-29 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 296,000 15.62
2014-01-24 2014-01-22 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 52,500 52,500
2014-01-03 2013-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (right to buy)
A - Award 25,000 25,000
2014-01-03 2013-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -5,854 171,032 -3.31 4.34 -25,406 742,279
2013-05-31 2013-05-30 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 40,000
2013-04-18 2013-04-15 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 50,000 50,000
2013-01-09 2013-01-07 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 52,500 52,500
2013-01-03 2012-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
F - Taxes -1,904 176,886 -1.06 4.21 -8,016 744,690
2013-01-03 2012-12-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
A - Award 17,546 178,790 10.88
2012-08-01 2012-07-30 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 17,500 17,500
2012-07-27 2012-07-23 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 35,000 35,000
2012-06-06 2012-06-05 4 CHTP Chelsea Therapeutics International, Ltd.
Common Stock
P - Purchase 4,900 450,178 1.10 1.32 6,468 594,190
2012-06-06 2012-06-05 4 CHTP Chelsea Therapeutics International, Ltd.
Common Stock
P - Purchase 100 445,278 0.02 1.32 132 587,767
2012-06-04 2012-05-31 4 EMIS EMISPHERE TECHNOLOGIES INC
Non-Qualified Stock Option (Right to Buy)
A - Award 40,000 216,000 22.73
2012-06-01 2012-05-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock Warrants (right to buy)
X - Other -35,566 0 -100.00
2012-06-01 2012-05-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
J - Other -27,844 161,244 -14.73 5.02 -139,777 809,445
2012-06-01 2012-05-31 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
X - Other 35,566 189,088 23.17 3.93 139,774 743,116
2012-01-27 2012-01-25 4 CHTP Chelsea Therapeutics International, Ltd.
Stock Option (Right to Buy)
A - Award 30,000 30,000
2012-01-04 2011-12-30 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock
A - Award 17,577 153,522 12.93
2011-05-26 2011-05-25 4 ZIOP ZIOPHARM ONCOLOGY INC
Common Stock, $.001 par value
S - Sale -15,000 135,945 -9.94 6.53 -97,950 887,721
2007-12-17 2007-12-12 4 ZIOP ZIOPHARM ONCOLOGY INC
Stock Option (right to buy)
A - Award 20,000 20,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)